Identification

Name
Pimecrolimus
Accession Number
DB00337  (APRD01182)
Type
Small Molecule
Groups
Approved, Investigational
Description

Pimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis, (however Galderma will be promoting the molecule in Canada in early 2007) under the trade name Elidel. [Wikipedia]

Structure
Thumb
Synonyms
  • 33-Epi-chloro-33-desoxyascomycin
  • Pimecrolimus
  • Pimecrolimusum
External IDs
ASM 981 / SDZ ASM 981 / SDZ ASM-981
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ElidelCream10 mg/gTopicalPhysicians Total Care, Inc.2003-10-30Not applicableUs
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America2001-12-02Not applicableUs
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America2001-12-02Not applicableUs
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America2001-12-02Not applicableUs
ElidelCream1 %TopicalValeant Canada Lp Valeant Canada S.E.C.2003-03-24Not applicableCanada
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America2001-12-02Not applicableUs
International/Other Brands
Aregen (Meda Pharm) / Rizan (Esteve)
Categories
UNII
7KYV510875
CAS number
137071-32-0
Weight
Average: 810.46
Monoisotopic: 809.4480897
Chemical Formula
C43H68ClNO11
InChI Key
KASDHRXLYQOAKZ-XDSKOBMDSA-N
InChI
InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
IUPAC Name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0⁴,⁹]octacos-18-ene-2,3,10,16-tetrone
SMILES
[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC

Pharmacology

Indication

For treatment of mild to moderate atopic dermatitis.

Associated Conditions
Pharmacodynamics

Pimecrolimus is a chemical that is used to treat atopic dermatitis (eczema). Atopic dermatitis is a skin condition characterized by redness, itching, scaling and inflammation of the skin. The cause of atopic dermatitis is not known; however, scientists believe that it may be due to activation of the immune system by various environmental or emotional triggers. Scientists do not know exactly how pimecrolimus reduces the manifestations of atopic dermatitis, but pimecrolimus reduces the action of T-cells and mast cells which are part of the immune system and contribute to responses of the immune system. Pimecrolimus prevents the activation of T-cells by blocking the effects of chemicals (cytokines) released by the body that stimulate T-cells. Pimecrolimus also reduces the ability of mast cells to release chemicals that promote inflammation.

Mechanism of action

Pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. Also, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/lgE.

TargetActionsOrganism
ASerine/threonine-protein kinase mTOR
potentiator
Human
UPeptidyl-prolyl cis-trans isomerase FKBP1A
potentiator
Human
Absorption

Because of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, Cmax, half-life, etc. cannot be reliably done.

Volume of distribution
Not Available
Protein binding

74%-87% (in vitro, bound to plasma proteins)

Metabolism

No drug metabolism was observed in human skin in vitro. Oral administration yielded metabolites produced from O-demethylation and oxygenation reactions.

Route of elimination

80% of the drug is excreted in the feces.

Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 2-Methoxyethanol.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 5-androstenedione.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Abatacept.Approved
AbciximabPimecrolimus may increase the anticoagulant activities of Abciximab.Approved
AbetimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Abetimus.Investigational
AcebutololPimecrolimus may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPimecrolimus may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acetaminophen.Approved
Acetyl sulfisoxazoleThe metabolism of Pimecrolimus can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acetylsalicylic acid.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pimecrolimus.Approved
AdefovirThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adefovir.Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Afelimomab.Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aldosterone.Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.Approved, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alendronic acid.Approved
AlicaforsenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alicaforsen.Investigational
AliskirenPimecrolimus may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alminoprofen.Experimental
AlprenololPimecrolimus may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pimecrolimus.Approved, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Altretamine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amcinonide.Approved
AmikacinPimecrolimus may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmiloridePimecrolimus may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amsacrine.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.Approved
AncrodPimecrolimus may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anisodamine.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anthrax immune globulin human.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antilymphocyte immunoglobulin (horse).Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antipyrine.Approved, Investigational
Antithrombin III humanPimecrolimus may increase the anticoagulant activities of Antithrombin III human.Approved
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antithymocyte immunoglobulin (rabbit).Approved
AntrafenineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Pimecrolimus can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanPimecrolimus may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Apocynin.Investigational
ApramycinPimecrolimus may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Pimecrolimus can be decreased when combined with Aprepitant.Approved, Investigational
ArbekacinPimecrolimus may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPimecrolimus may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPimecrolimus may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPimecrolimus may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapinePimecrolimus may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Atamestane.Investigational
AtazanavirThe metabolism of Pimecrolimus can be decreased when combined with Atazanavir.Approved, Investigational
AtenololPimecrolimus may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Pimecrolimus can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Atorvastatin.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azacitidine.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azelastine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pimecrolimus.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Pimecrolimus.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Balsalazide.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pimecrolimus.Investigational
BecaplerminPimecrolimus may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPimecrolimus may decrease the antihypertensive activities of Befunolol.Experimental
BegelomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Begelomab.Experimental, Investigational
BekanamycinPimecrolimus may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BelataceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belatacept.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belimumab.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pimecrolimus.Approved
BenorilateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benoxaprofen.Withdrawn
BenznidazoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole.Approved, Investigational
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Pimecrolimus.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pimecrolimus.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.Approved, Vet Approved
BetaxololPimecrolimus may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Pimecrolimus.Approved, Investigational
BevantololPimecrolimus may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
BisoprololPimecrolimus may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPimecrolimus may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BleomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bleomycin.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Blinatumomab.Approved, Investigational
BoceprevirThe metabolism of Pimecrolimus can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololPimecrolimus may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Pimecrolimus can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pimecrolimus can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Briakinumab.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brodalumab.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bucillamine.Investigational
BucindololPimecrolimus may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bufexamac.Approved, Experimental
BufuralolPimecrolimus may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Pimecrolimus.Approved
BupranololPimecrolimus may decrease the antihypertensive activities of Bupranolol.Approved
BusulfanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Busulfan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Canakinumab.Approved, Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pimecrolimus.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pimecrolimus.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Candoxatril.Experimental
CapecitabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Captopril.Approved
CarbamazepineThe metabolism of Pimecrolimus can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pimecrolimus.Approved
CarmustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carmustine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPimecrolimus may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPimecrolimus may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Celecoxib.Approved, Investigational
CeliprololPimecrolimus may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Pimecrolimus can be increased when it is combined with Ceritinib.Approved
CerivastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Cerivastatin.Approved, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Certolizumab pegol.Approved
CertoparinPimecrolimus may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorambucilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorambucil.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pimecrolimus.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cimicoxib.Investigational
CinoxacinPimecrolimus may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinPimecrolimus may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.Approved
Citric AcidPimecrolimus may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
CladribineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Pimecrolimus can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pimecrolimus can be decreased when combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clofarabine.Approved, Investigational
ClonixinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pimecrolimus.Vet Approved
CloranololPimecrolimus may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Pimecrolimus can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Pimecrolimus can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pimecrolimus.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Corticosterone.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibThe metabolism of Pimecrolimus can be decreased when combined with Crizotinib.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pimecrolimus.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.Approved, Investigational
Dabigatran etexilatePimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dacarbazine.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dactinomycin.Approved, Investigational
DalteparinPimecrolimus may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPimecrolimus may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPimecrolimus may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Pimecrolimus can be decreased when combined with Darunavir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pimecrolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Delapril.Investigational
DelavirdineThe metabolism of Pimecrolimus can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pimecrolimus.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Deoxyspergualin.Investigational
DesipraminePimecrolimus may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinPimecrolimus may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pimecrolimus.Approved, Investigational
DextranPimecrolimus may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinPimecrolimus may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pimecrolimus.Approved, Vet Approved
DicoumarolPimecrolimus may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pimecrolimus.Approved
DihydroergotamineThe metabolism of Pimecrolimus can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydrostreptomycinPimecrolimus may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Pimecrolimus can be decreased when combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dimethyl fumarate.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Pimecrolimus.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pimecrolimus.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxifluridine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pimecrolimus can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Pimecrolimus can be decreased when combined with Dronedarone.Approved
DrospirenonePimecrolimus may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Pimecrolimus is combined with E-6201.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Eculizumab.Approved, Investigational
Edetic AcidPimecrolimus may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPimecrolimus may increase the anticoagulant activities of Edoxaban.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Enalaprilat.Approved
EnoxacinPimecrolimus may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPimecrolimus may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Pimecrolimus.Experimental
EnzalutamideThe serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide.Approved
EpanololPimecrolimus may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirubicin.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Pimecrolimus.Experimental
EplerenonePimecrolimus may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pimecrolimus.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pimecrolimus.Approved
EquileninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilin.Approved
ErythromycinThe metabolism of Pimecrolimus can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololPimecrolimus may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololPimecrolimus may decrease the antihypertensive activities of Esmolol.Approved
EstramustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estramustine.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pimecrolimus.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePimecrolimus may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etofenamate.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Evening primrose oil.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Everolimus.Approved
ExisulindThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Pimecrolimus.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Feprazone.Experimental
Ferulic acidPimecrolimus may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pimecrolimus.Approved, Investigational
FingolimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fingolimod.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fish oil.Approved, Nutraceutical
FleroxacinPimecrolimus may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pimecrolimus.Approved, Withdrawn
FloxuridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Pimecrolimus can be decreased when combined with Fluconazole.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.Approved, Investigational
FluindionePimecrolimus may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequinePimecrolimus may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Pimecrolimus.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone propionate.Approved
FluvastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Pimecrolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pimecrolimus.Approved, Nutraceutical, Vet Approved
FondaparinuxPimecrolimus may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pimecrolimus.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Pimecrolimus can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pimecrolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Pimecrolimus can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinPimecrolimus may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
Fusidic AcidThe serum concentration of Pimecrolimus can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with G17DT.Investigational
GabexatePimecrolimus may increase the anticoagulant activities of Gabexate.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gallium nitrate.Approved, Investigational
GarenoxacinPimecrolimus may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPimecrolimus may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemcitabine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pimecrolimus.Approved, Withdrawn
GemifloxacinPimecrolimus may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.Approved, Investigational
GeneticinPimecrolimus may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPimecrolimus may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APimecrolimus may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Pimecrolimus is combined with GI-5005.Investigational
GinsengThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ginseng.Approved, Investigational, Nutraceutical
GlatiramerThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glatiramer Acetate.Approved, Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glimepiride.Approved
GolimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Golimumab.Approved
GrepafloxacinPimecrolimus may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GS 0573The risk or severity of adverse effects can be increased when Pimecrolimus is combined with GS 0573.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Guacetisal.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gusperimus.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Pimecrolimus is combined with HE3286.Investigational
HeparinPimecrolimus may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Higenamine.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Human C1-esterase inhibitor.Approved
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Human rabies virus immune globulin.Approved
HydralazinePimecrolimus may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
HydroxyureaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydroxyurea.Approved
Hygromycin BPimecrolimus may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hypericin.Investigational
IbandronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icosapent.Approved, Nutraceutical
IdarubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idarubicin.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idelalisib.Approved
IdraparinuxPimecrolimus may increase the anticoagulant activities of Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ifosfamide.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imidazole salicylate.Experimental
ImiquimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imiquimod.Approved, Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus.Approved
IndenololPimecrolimus may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Pimecrolimus can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indoprofen.Withdrawn
InfliximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.Approved
INGN 201The risk or severity of adverse effects can be increased when Pimecrolimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pimecrolimus is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Pimecrolimus can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Pimecrolimus can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinPimecrolimus may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Pimecrolimus can be decreased when combined with Isradipine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Pimecrolimus can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pimecrolimus can be increased when it is combined with Ivacaftor.Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinPimecrolimus may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Pimecrolimus can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pimecrolimus.Approved
L-PhenylalanineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with L-Phenylalanine.Approved, Investigational, Nutraceutical
LabetalolPimecrolimus may decrease the antihypertensive activities of Labetalol.Approved
LandiololPimecrolimus may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Pimecrolimus.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.Approved
LepirudinPimecrolimus may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPimecrolimus may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololPimecrolimus may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololPimecrolimus may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPimecrolimus may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Pimecrolimus.Experimental
LomefloxacinPimecrolimus may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lomustine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lonazolac.Experimental
LopinavirThe metabolism of Pimecrolimus can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Pimecrolimus can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Loteprednol.Approved
LovastatinThe metabolism of Pimecrolimus can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
LuliconazoleThe serum concentration of Pimecrolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Pimecrolimus can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Pimecrolimus.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pimecrolimus.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Pimecrolimus is combined with ME-609.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mechlorethamine.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mefenamic acid.Approved
MelagatranPimecrolimus may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melphalan.Approved
MepindololPimecrolimus may decrease the antihypertensive activities of Mepindolol.Experimental
MepolizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mepolizumab.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mercaptopurine.Approved
MesalazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Metamizole.Approved, Investigational, Withdrawn
MethotrexateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methotrexate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPimecrolimus may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.Approved
MetoprololPimecrolimus may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MevastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Mevastatin.Experimental
MicronomicinPimecrolimus may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Pimecrolimus.Approved, Experimental
MifepristoneThe serum concentration of Pimecrolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pimecrolimus.Approved
MitomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitomycin.Approved
MitotaneThe serum concentration of Pimecrolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pimecrolimus.Approved
MoxifloxacinPimecrolimus may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nabumetone.Approved
NadololPimecrolimus may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPimecrolimus may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naftifine.Approved
Nalidixic AcidPimecrolimus may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Pimecrolimus is combined with NCX 1022.Investigational
NeaminePimecrolimus may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPimecrolimus may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Pimecrolimus can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Pimecrolimus can be decreased when combined with Nelfinavir.Approved
NemonoxacinPimecrolimus may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPimecrolimus may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nepafenac.Approved, Investigational
NetilmicinPimecrolimus may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Pimecrolimus can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Pimecrolimus can be decreased when combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Niflumic Acid.Approved
NilotinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nitroaspirin.Investigational
NorfloxacinPimecrolimus may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Obinutuzumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Pimecrolimus.Approved, Investigational
OfloxacinPimecrolimus may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Pimecrolimus can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pimecrolimus.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.Approved
OlsalazinePimecrolimus may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Pimecrolimus is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Pimecrolimus can be increased when it is combined with Osimertinib.Approved
OtamixabanPimecrolimus may increase the anticoagulant activities of Otamixaban.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.Approved
Oxolinic acidPimecrolimus may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPimecrolimus may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pamidronate.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Panobinostat.Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paquinimod.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Parecoxib.Approved
ParomomycinPimecrolimus may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Parthenolide.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.Approved
PazufloxacinPimecrolimus may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPimecrolimus may increase the neuroexcitatory activities of Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.Approved, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.Approved, Investigational
PenbutololPimecrolimus may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePimecrolimus may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Pimecrolimus can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfatePimecrolimus may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentostatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pentostatin.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Perindopril.Approved
PhenindionePimecrolimus may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Pimecrolimus can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonPimecrolimus may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Pimecrolimus can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPimecrolimus may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidPimecrolimus may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirarubicin.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Pimecrolimus.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirfenidone.Approved, Investigational
Piromidic acidPimecrolimus may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirprofen.Experimental
PitavastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Pitavastatin.Approved
PitolisantThe serum concentration of Pimecrolimus can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorPimecrolimus may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPimecrolimus may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pimecrolimus.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Pimecrolimus can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitratePimecrolimus may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololPimecrolimus may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pralatrexate.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prasterone sulfate.Investigational
PravastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Pravastatin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Pimecrolimus can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Pimecrolimus can be increased when it is combined with Probenecid.Approved, Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Procarbazine.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propacetamol.Approved, Investigational
PropafenonePimecrolimus may decrease the antihypertensive activities of Propafenone.Approved
PropranololPimecrolimus may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Pimecrolimus.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Pimecrolimus.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Pimecrolimus.Vet Approved
Protein CPimecrolimus may increase the anticoagulant activities of Protein C.Approved
Protein S humanPimecrolimus may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePimecrolimus may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPimecrolimus may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Pimecrolimus is combined with PTC299.Investigational
PuromycinPimecrolimus may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pimecrolimus.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pimecrolimus.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ramipril.Approved
RanolazineThe metabolism of Pimecrolimus can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinPimecrolimus may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPimecrolimus may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Pimecrolimus can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Pimecrolimus can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pimecrolimus can be increased when combined with Rifapentine.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rilonacept.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rindopepimut.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Risedronate.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.Approved
RivaroxabanPimecrolimus may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pimecrolimus.Approved
RosoxacinPimecrolimus may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Rosuvastatin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe metabolism of Pimecrolimus can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinPimecrolimus may increase the neuroexcitatory activities of Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Pimecrolimus.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylic acid.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pimecrolimus.Experimental
SaquinavirThe metabolism of Pimecrolimus can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pimecrolimus.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Pimecrolimus.Approved, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Secukinumab.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Semapimod.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seocalcitol.Experimental, Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Pimecrolimus can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pimecrolimus can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pimecrolimus.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sirolimus.Approved, Investigational
SisomicinPimecrolimus may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPimecrolimus may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitratePimecrolimus may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicSodium phosphate may increase the nephrotoxic activities of Pimecrolimus.Approved
SorafenibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.Approved, Investigational
SotalolPimecrolimus may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinPimecrolimus may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Spirapril.Approved
SpironolactonePimecrolimus may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Pimecrolimus is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Pimecrolimus is combined with SRT501.Investigational
St. John's WortThe serum concentration of Pimecrolimus can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
SteproninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Stepronin.Approved
StiripentolThe serum concentration of Pimecrolimus can be increased when it is combined with Stiripentol.Approved
StreptomycinPimecrolimus may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Streptozocin.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Pimecrolimus can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulindac.Approved, Investigational
SulodexidePimecrolimus may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Pimecrolimus.Investigational
SunitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suxibuzone.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Pimecrolimus.Approved
TalinololPimecrolimus may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pimecrolimus.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pimecrolimus.Approved
TecemotideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tecemotide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Pimecrolimus can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Pimecrolimus can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus.Approved, Investigational
TemafloxacinPimecrolimus may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temocapril.Experimental, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenidap.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teniposide.Approved
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tepoxalin.Vet Approved
TerbutalinePimecrolimus may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teriflunomide.Approved
TertatololPimecrolimus may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The risk or severity of adverse effects can be increased when Pimecrolimus is combined with TG4010.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thiotepa.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Pimecrolimus can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPimecrolimus may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tinoridine.Investigational
TioguanineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tioguanine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tixocortol.Approved, Withdrawn
TobramycinPimecrolimus may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolmetin.Approved
TopotecanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Topotecan.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Pimecrolimus.Approved
TositumomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trabectedin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Pimecrolimus.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trastuzumab emtansine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pimecrolimus.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pimecrolimus.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triamcinolone.Approved, Vet Approved
TriamterenePimecrolimus may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trofosfamide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trolamine salicylate.Approved
TrovafloxacinPimecrolimus may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPimecrolimus may increase the anticoagulant activities of Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
UstekinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ustekinumab.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pimecrolimus.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pimecrolimus.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VedolizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vedolizumab.Approved
VemurafenibThe serum concentration of Pimecrolimus can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Pimecrolimus can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vilanterol.Approved
VinblastineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vindesine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinorelbine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Voclosporin.Investigational
VoriconazoleThe metabolism of Pimecrolimus can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPimecrolimus may increase the anticoagulant activities of Warfarin.Approved
WortmanninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Wortmannin.Experimental
XimelagatranPimecrolimus may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Pimecrolimus can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Viktor Gyollai, Csaba Szabo, "Methods of preparing pimecrolimus." U.S. Patent US20060142564, issued June 29, 2006.

US20060142564
General References
  1. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 Aug;141(2):264-73. [PubMed:10468798]
External Links
PubChem Compound
6509979
PubChem Substance
46505748
ChemSpider
21111755
ChEBI
135888
ChEMBL
CHEMBL1200686
Therapeutic Targets Database
DAP000594
PharmGKB
PA164783790
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Pimecrolimus
ATC Codes
D11AH02 — Pimecrolimus
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
FDA label
Download (230 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAtopic Dermatitis (AD)1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentHealthy Volunteers1
1, 2CompletedTreatmentNetherton Syndrome1
2CompletedTreatmentAtopic Dermatitis (AD)3
2CompletedTreatmentLichen Sclerosus et Atrophicus1
2CompletedTreatmentOral Lichen Planus1
2CompletedTreatmentPrurigo Nodularis1
2CompletedTreatmentSeborrheic Dermatitis1
2TerminatedTreatmentOral Erosive Lichen Planus1
2Unknown StatusSupportive CareRash1
3CompletedTreatmentAtopic Dermatitis (AD)7
3CompletedTreatmentChronic Hand Dermatitis1
3CompletedTreatmentLichen Planus, Oral1
3CompletedTreatmentPerioral Dermatitis1
4CompletedTreatmentAtopic Dermatitis (AD)18
4CompletedTreatmentMild to Moderate Atopic Dermatitis1
4CompletedTreatmentOral Lichen Planus1
4RecruitingTreatmentAtopic Dermatitis (AD)1
4TerminatedTreatmentAtopic Dermatitis (AD)2
4Unknown StatusTreatmentVitiligo1
Not AvailableCompletedTreatmentAtopic Dermatitis (AD)1
Not AvailableCompletedTreatmentDiscoid Lupus Erythematosus (DLE)1
Not AvailableCompletedTreatmentKeratoconjunctivitis Sicca1
Not AvailableCompletedTreatmentModerate to Severe Atopic Dermatitis1
Not AvailableRecruitingNot AvailableAtopic Dermatitis (AD)1
Not AvailableWithdrawnTreatmentLupus Erythematosus, Cutaneous / Lupus Erythematosus, Discoid1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
  • Novartis AG
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
CreamTopical1 %
CreamTopical10 mg/g
Prices
Unit descriptionCostUnit
Elidel 100 Gram Tube 1% 100 gm Tube315.76USD tube
Elidel 60 Gram Tube 1% 60 gm Tube200.05USD tube
Elidel 30 Gram Tube 1% 30 gm Tube101.44USD tube
Elidel 1% cream3.21USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2200966No2006-12-192015-10-26Canada
US5912238Yes1996-12-152016-12-15Us
US6352998Yes1996-04-262016-04-26Us
US6423722Yes1998-12-262018-12-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP4.36ALOGPS
logP6.81ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area158.13 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity214.03 m3·mol-1ChemAxon
Polarizability87.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6208
Blood Brain Barrier-0.9554
Caco-2 permeable-0.5764
P-glycoprotein substrateSubstrate0.8064
P-glycoprotein inhibitor IInhibitor0.8064
P-glycoprotein inhibitor IIInhibitor0.7014
Renal organic cation transporterNon-inhibitor0.8556
CYP450 2C9 substrateNon-substrate0.9117
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.7519
CYP450 1A2 substrateNon-inhibitor0.8678
CYP450 2C9 inhibitorNon-inhibitor0.8671
CYP450 2D6 inhibitorNon-inhibitor0.9026
CYP450 2C19 inhibitorNon-inhibitor0.8248
CYP450 3A4 inhibitorNon-inhibitor0.8672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9326
Ames testNon AMES toxic0.6495
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.6919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.6886
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolide lactams
Sub Class
Not Available
Direct Parent
Macrolide lactams
Alternative Parents
Alpha amino acid esters / Macrolides and analogues / Cyclohexyl halides / Oxanes / Piperidines / Tertiary carboxylic acid amides / Carboxylic acid esters / Cyclic ketones / Hemiacetals / Lactams
show 12 more
Substituents
Macrolide lactam / Alpha-amino acid ester / Macrolide / Alpha-amino acid or derivatives / Cyclohexyl halide / Oxane / Piperidine / Tertiary carboxylic acid amide / Carboxamide group / Carboxylic acid ester
show 27 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Tfiiic-class transcription factor binding
Specific Function
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly...
Gene Name
MTOR
Uniprot ID
P42345
Uniprot Name
Serine/threonine-protein kinase mTOR
Molecular Weight
288889.05 Da
References
  1. Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8. [PubMed:12113647]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Potentiator
General Function
Type i transforming growth factor beta receptor binding
Specific Function
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevent...
Gene Name
FKBP1A
Uniprot ID
P62942
Uniprot Name
Peptidyl-prolyl cis-trans isomerase FKBP1A
Molecular Weight
11950.665 Da
References
  1. Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8. [PubMed:12113647]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U, Baldeck JP, Schweitzer A, Berthier S, Moenius T, Grassberger MA: Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74. Epub 2006 Feb 7. [PubMed:16467136]

Drug created on June 13, 2005 07:24 / Updated on July 16, 2018 21:12